Glenmark Pharmaceuticals is currently trading at Rs. 536.20, up by 0.35 points or 0.07% from its previous closing of Rs. 535.85 on the BSE.
The scrip opened at Rs. 532.00 and has touched a high and low of Rs. 544.70 and Rs. 528.35 respectively. So far 83,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 550.50 on 27-Dec-2012 and a 52 week low of Rs. 286.15 on 07-Mar-2012.
Last one week high and low of the scrip stood at Rs. 550.50 and Rs. 526.10 respectively. The current market cap of the company is Rs. 14,516 crore.
The promoters holding in the company stood at 48.33% while Institutions and Non-Institutions held 39.85% and 11.82% respectively.
Glenmark Generics Inc., USA, the United States subsidiary of Glenmark Generics has been granted final approval from the United States Food and Drug Administration (USFDA) for Rizatriptan Benzoate Tablets, its generic version of Merck’s Maxalt Tablets. The company has commenced shipping immediately upon approval.
The approval is for the 5 mg and 10 mg of Rizatriptan. According to IMS Health for the 12 month period ending Sept 2012, Rizatriptan Benzoate Tablets achieved sales of $333 million.
Glenmark’s current portfolio consists of 82 products authorized for distribution in the US, marketplace and 46 ANDA’s pending approval with the USFDA. Besides, the company remains focused on strategic planning and development and continues its aggressive filing schedule for new ANDA submissions.
Glenmark Generics is a subsidiary of Glenmark Pharmaceuticals (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1826.10 |
| Dr. Reddys Lab | 1371.60 |
| Cipla | 1488.15 |
| Lupin | 2251.80 |
| Zydus Lifesciences | 1009.40 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
